Tags

Type your tag names separated by a space and hit enter

Alteraciones de la coagulación en la COVID-19.
Cir Cir. 2020; 88(6):787-793.CC

Abstract

Infection with the SARS-CoV-2 virus and the development of all manifestations of COVID-19, predisposes to arterial and venous thromboembolic disease. The coagulation system can be activated by various viruses, including SARS-CoV-2. Vascular endothelial damage, added to the development of disseminated intravascular coagulation, affects the prognosis and mortality from this disease. Treatment is aimed at the prevention, early detection and timely interventions of all coagulation disorders generated by COVID-19. The recommended anticoagulant is low molecular weight heparin, taking into account creatinine clearance, and if major invasive procedures will be performed, unfractionated heparin is a safe option.

Authors+Show Affiliations

Centro Nacional de Investigación y Atención en Quemados, Instituto Nacional de Rehabilitación, Ciudad de México, México.Centro Nacional de Investigación y Atención en Quemados, Instituto Nacional de Rehabilitación, Ciudad de México, México.Centro Nacional de Investigación y Atención en Quemados, Instituto Nacional de Rehabilitación, Ciudad de México, México.Centro Nacional de Investigación y Atención en Quemados, Instituto Nacional de Rehabilitación, Ciudad de México, México.Centro Nacional de Investigación y Atención en Quemados, Instituto Nacional de Rehabilitación, Ciudad de México, México.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33254192

Citation

Carrillo-Esper, Raúl, et al. "Alteraciones De La Coagulación En La COVID-19." Cirugia Y Cirujanos, vol. 88, no. 6, 2020, pp. 787-793.
Carrillo-Esper R, Melgar-Bieberach RE, Jacinto-Flores SA, et al. Alteraciones de la coagulación en la COVID-19. Cir Cir. 2020;88(6):787-793.
Carrillo-Esper, R., Melgar-Bieberach, R. E., Jacinto-Flores, S. A., Tapia-Salazar, M., & Campa-Mendoza, Á. N. (2020). Alteraciones de la coagulación en la COVID-19. Cirugia Y Cirujanos, 88(6), 787-793. https://doi.org/10.24875/CIRU.20000416
Carrillo-Esper R, et al. Alteraciones De La Coagulación En La COVID-19. Cir Cir. 2020;88(6):787-793. PubMed PMID: 33254192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alteraciones de la coagulación en la COVID-19. AU - Carrillo-Esper,Raúl, AU - Melgar-Bieberach,Rebeca E, AU - Jacinto-Flores,Sarahi A, AU - Tapia-Salazar,Mauricio, AU - Campa-Mendoza,Ángela N, PY - 2020/11/30/entrez PY - 2020/12/1/pubmed PY - 2020/12/15/medline KW - Coagulación intravascular diseminada KW - Heparina de bajo peso molecular KW - Immunothrombosis KW - Inmunotrombosis KW - Intravascular disseminated coagulation KW - Low molecular weight heparin KW - Tromboembolia venosa KW - Venous thromboembolism SP - 787 EP - 793 JF - Cirugia y cirujanos JO - Cir Cir VL - 88 IS - 6 N2 - Infection with the SARS-CoV-2 virus and the development of all manifestations of COVID-19, predisposes to arterial and venous thromboembolic disease. The coagulation system can be activated by various viruses, including SARS-CoV-2. Vascular endothelial damage, added to the development of disseminated intravascular coagulation, affects the prognosis and mortality from this disease. Treatment is aimed at the prevention, early detection and timely interventions of all coagulation disorders generated by COVID-19. The recommended anticoagulant is low molecular weight heparin, taking into account creatinine clearance, and if major invasive procedures will be performed, unfractionated heparin is a safe option. SN - 2444-054X UR - https://www.unboundmedicine.com/medline/citation/33254192/Alteraciones_de_la_coagulación_en_la_COVID_19_ L2 - http://cirugiaycirujanos.com/frame_esp.php?id=393 DB - PRIME DP - Unbound Medicine ER -